Drug Dosage Testing using Surface-enhanced Raman Spectroscopy

THE CHALLENGE

Plasmonic nanostructures have enabled label-free surfaceenhanced Raman spectroscopy (SERS) to emerge as a rapid nondestructive molecular fingerprint characterization technique for complex biological samples. However, label-free SERs bioanalysis faces significant challenges in reliability and reproducibility due to local optical field variations at plasmonic hotspots.

 

OUR SOLUTION

The Zhou lab has shown that plasmonically enhanced electronic Raman scattering (ERS) signals from metal nanostructures can serve as a SERS calibration internal standard to improve multivariate analysis of living biological systems. ERS-based SERS calibration can enhance supervised learning classification of label-free living cell SERS spectra in (1) subtyping breast cancer cells with different degrees of malignancy and (2) assessing cancer cells' drug responses at different dosages.

 

A flow diagram illustrates the major steps of ERS calibration-enabled improved multivariate analysis of living cells SERS. Cells are prepared in culture and treated with drugs. Conventional SERS analysis yields convoluted multivariate results with overlapping clusters, while plasmonic ERS leads to more separation between clusters with different drug doses.

 

A scheme for a 2D label-free SERS measurement of living breast normal cells and cancer cells cultures on the nanolaminated SERS substrates.

Patent Information:
For Information, Contact:
Emily Lanier
Licensing Manager
Virginia Tech Intellectual Properties, Inc.
emilylt@vt.edu
Inventors:
Wei Zhou
Wonil Nam
Keywords: